{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:33:43Z","timestamp":1790354023680,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","award":["IRT14R20"],"award-info":[{"award-number":["IRT14R20"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005890","name":"Ministry of Health of the People's Republic of China","doi-asserted-by":"publisher","award":["2017ZX10202201"],"award-info":[{"award-number":["2017ZX10202201"]}],"id":[{"id":"10.13039\/501100005890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81171558"],"award-info":[{"award-number":["81171558"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81271808"],"award-info":[{"award-number":["81271808"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.antiviral.2017.10.003","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T02:00:55Z","timestamp":1507773655000},"page":"75-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection"],"prefix":"10.1016","volume":"147","author":[{"given":"Meifang","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.antiviral.2017.10.003_bib1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jhep.2013.10.021","article-title":"Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration","volume":"60","author":"Allweiss","year":"2014","journal-title":"J. Hepatol."},{"issue":"17","key":"10.1016\/j.antiviral.2017.10.003_bib2","doi-asserted-by":"crossref","first-page":"11045","DOI":"10.1128\/JVI.79.17.11045-11052.2005","volume":"79","author":"Anderson","year":"2005","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2017.10.003_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0092-8674(90)90239-B","article-title":"Transgenic mice with intracellular immunity to influenza virus","volume":"62","author":"Arnheiter","year":"1990","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.antiviral.2017.10.003_bib4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.antiviral.2017.10.003_bib5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1096\/fj.02-0664fje","article-title":"IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3","volume":"17","author":"Bode","year":"2003","journal-title":"Faseb J."},{"issue":"4","key":"10.1016\/j.antiviral.2017.10.003_bib6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/hep.26657","article-title":"Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression","volume":"59","author":"Bolen","year":"2014","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.antiviral.2017.10.003_bib7","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2017.10.003_bib8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jhep.2013.06.001","article-title":"Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes","volume":"59","author":"Brownell","year":"2013","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.antiviral.2017.10.003_bib9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/1389203043379378","article-title":"Alpha-interferon and its effects on signalling pathways within cells","volume":"5","author":"Caraglia","year":"2004","journal-title":"Curr. Protein Pept. Sci."},{"issue":"Pt 2","key":"10.1016\/j.antiviral.2017.10.003_bib10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1099\/vir.0.015388-0","article-title":"ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment","volume":"91","author":"Chen","year":"2010","journal-title":"J. Gen. Virol."},{"issue":"9","key":"10.1016\/j.antiviral.2017.10.003_bib11","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.3390\/ijms11093501","article-title":"Interferon-alpha induces high expression of APOBEC3G and STAT-1 in vitro and in vivo","volume":"11","author":"Chen","year":"2010","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.antiviral.2017.10.003_bib12","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1053\/gast.2002.36026","article-title":"Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection","volume":"123","author":"Chen","year":"2002","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.antiviral.2017.10.003_bib13","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1084\/jem.20072076","article-title":"Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection","volume":"205","author":"Das","year":"2008","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.antiviral.2017.10.003_bib14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/jvh.12494","article-title":"Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C","volume":"23","author":"Duarte-Rojo","year":"2016","journal-title":"J. Viral Hepat."},{"issue":"9","key":"10.1016\/j.antiviral.2017.10.003_bib15","doi-asserted-by":"crossref","first-page":"e1005103","DOI":"10.1371\/journal.ppat.1005103","article-title":"Intrahepatic transcriptional signature associated with response to interferon-alpha treatment in the woodchuck model of chronic hepatitis B","volume":"11","author":"Fletcher","year":"2015","journal-title":"PLoS Pathog."},{"issue":"12","key":"10.1016\/j.antiviral.2017.10.003_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.it.2003.10.008","article-title":"Regulation of cytokine signaling by SOCS family molecules","volume":"24","author":"Fujimoto","year":"2003","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.antiviral.2017.10.003_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3851\/IMP3019","article-title":"Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-alpha2a: 1 year follow-up of the OSST study","volume":"21","author":"Han","year":"2016","journal-title":"Antivir. Ther."},{"issue":"47","key":"10.1016\/j.antiviral.2017.10.003_bib18","doi-asserted-by":"crossref","first-page":"32715","DOI":"10.1074\/jbc.M806769200","article-title":"Hepatitis B virus-induced hFGL2 transcription is dependent on c-Ets-2 and MAPK signal pathway","volume":"283","author":"Han","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.antiviral.2017.10.003_bib19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.gastro.2010.04.049","article-title":"Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C","volume":"139","author":"Honda","year":"2010","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.antiviral.2017.10.003_bib20","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1073\/pnas.80.7.1910","article-title":"Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus","volume":"80","author":"Horisberger","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"21","key":"10.1016\/j.antiviral.2017.10.003_bib21","doi-asserted-by":"crossref","first-page":"12254","DOI":"10.1128\/JVI.00775-14","article-title":"Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection","volume":"88","author":"Hou","year":"2014","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2017.10.003_bib22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1053\/j.gastro.2006.11.045","article-title":"Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C","volume":"132","author":"Huang","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.antiviral.2017.10.003_bib23","doi-asserted-by":"crossref","first-page":"e8649","DOI":"10.1371\/journal.pone.0008649","article-title":"Hepatitis B virus X protein impairs hepatic insulin signaling through degradation of IRS1 and induction of SOCS3","volume":"5","author":"Kim","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.antiviral.2017.10.003_bib24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2008.12.021","article-title":"Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV\/HIV infection","volume":"50","author":"Kim","year":"2009","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.antiviral.2017.10.003_bib25","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/gut.2005.070060","article-title":"Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies","volume":"55","author":"Larrea","year":"2006","journal-title":"Gut"},{"issue":"13","key":"10.1016\/j.antiviral.2017.10.003_bib26","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1128\/JVI.00236-10","article-title":"Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S\/S RNAs","volume":"84","author":"Li","year":"2010","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2017.10.003_bib27","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/hep.25608","article-title":"MxA inhibits hepatitis B virus replication by interaction with hepatitis B core antigen","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.antiviral.2017.10.003_bib28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/jgm.1174","article-title":"Inhibition of HBV gene expression and replication by stably expressed interferon-alpha1 via adeno-associated viral vectors","volume":"10","author":"Li","year":"2008","journal-title":"J. Gene Med."},{"issue":"3","key":"10.1016\/j.antiviral.2017.10.003_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol. Int."},{"issue":"18","key":"10.1016\/j.antiviral.2017.10.003_bib30","doi-asserted-by":"crossref","first-page":"10626","DOI":"10.1073\/pnas.95.18.10626","article-title":"Inhibition of Stat1-mediated gene activation by PIAS1","volume":"95","author":"Liu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.antiviral.2017.10.003_bib31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"Liver","year":"2012","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.antiviral.2017.10.003_bib32","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"issue":"6176","key":"10.1016\/j.antiviral.2017.10.003_bib33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.antiviral.2017.10.003_bib34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol. Int."},{"issue":"6","key":"10.1016\/j.antiviral.2017.10.003_bib35","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2009.01.016","article-title":"High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study","volume":"50","author":"Moucari","year":"2009","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.antiviral.2017.10.003_bib36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.antiviral.2017.10.003_bib37","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jhep.2005.06.019","article-title":"Human MxA protein participates to the interferon-related inhibition of hepatitis B virus replication in female transgenic mice","volume":"43","author":"Peltekian","year":"2005","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.antiviral.2017.10.003_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/jmv.23481","article-title":"Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment","volume":"85","author":"Pham","year":"2013","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2017.10.003_bib39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12072-011-9280-0","article-title":"Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients","volume":"7","author":"Piratvisuth","year":"2013","journal-title":"Hepatol. Int."},{"issue":"6","key":"10.1016\/j.antiviral.2017.10.003_bib40","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1073\/pnas.0308340100","article-title":"Signal transduction pathways that inhibit hepatitis B virus replication","volume":"101","author":"Robek","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.antiviral.2017.10.003_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2443.1999.00263.x","article-title":"Cytokine-inducible SH2 protein-3 (CIS3\/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain","volume":"4","author":"Sasaki","year":"1999","journal-title":"Genes Cells"},{"issue":"6","key":"10.1016\/j.antiviral.2017.10.003_bib42","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"issue":"3","key":"10.1016\/j.antiviral.2017.10.003_bib43","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.antiviral.2017.10.003_bib44","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.antiviral.2017.10.003_bib45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.antiviral.2017.10.003_bib46","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","article-title":"Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers","volume":"51","author":"Thompson","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.antiviral.2017.10.003_bib47","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.04.046","article-title":"Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters","volume":"141","author":"Tseng","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.antiviral.2017.10.003_bib48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27805","article-title":"Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells","volume":"62","author":"Vanwolleghem","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.antiviral.2017.10.003_bib49","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.22751","article-title":"Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells","volume":"49","author":"Wu","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.antiviral.2017.10.003_bib50","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.antiviral.2017.10.003_bib51","first-page":"1053","article-title":"Analysis of gene expression in hepatitis B virus transfected cell line induced by interferon","volume":"35","author":"Xiong","year":"2003","journal-title":"Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)"},{"issue":"6","key":"10.1016\/j.antiviral.2017.10.003_bib52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3851\/IMP2953","article-title":"Upregulation of NKG2C natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB","volume":"20","author":"Yan","year":"2015","journal-title":"Antivir. Ther."},{"issue":"11","key":"10.1016\/j.antiviral.2017.10.003_bib53","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1440-1746.2007.04985.x","article-title":"Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro","volume":"23","author":"Zhang","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.antiviral.2017.10.003_bib54","first-page":"112","article-title":"Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression","volume":"10","author":"Zhang","year":"2008","journal-title":"Cell Microbiol."},{"issue":"9","key":"10.1016\/j.antiviral.2017.10.003_bib55","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1089\/jir.2005.25.528","article-title":"Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance","volume":"25","author":"Zhu","year":"2005","journal-title":"J. Interferon Cytokine Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216302856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216302856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T05:51:00Z","timestamp":1656222660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216302856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":55,"alternative-id":["S0166354216302856"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.10.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}